» Articles » PMID: 27649868

The Draft Genome of Mycobacterium Aurum, a Potential Model Organism for Investigating Drugs Against Mycobacterium Tuberculosis and Mycobacterium Leprae

Overview
Date 2016 Sep 22
PMID 27649868
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium aurum (M. aurum) is an environmental mycobacteria that has previously been used in studies of anti-mycobacterial drugs due to its fast growth rate and low pathogenicity. The M. aurum genome has been sequenced and assembled into 46 contigs, with a total length of 6.02Mb containing 5684 annotated protein-coding genes. A phylogenetic analysis using whole genome alignments positioned M. aurum close to Mycobacterium vaccae and Mycobacterium vanbaalenii, within a clade related to fast-growing mycobacteria. Large-scale genomic rearrangements were identified by comparing the M. aurum genome to those of Mycobacterium tuberculosis and Mycobacterium leprae. M. aurum orthologous genes implicated in resistance to anti-tuberculosis drugs in M. tuberculosis were observed. The sequence identity at the DNA level varied from 68.6% for pncA (pyrazinamide drug-related) to 96.2% for rrs (streptomycin, capreomycin). We observed two homologous genes encoding the catalase-peroxidase enzyme (katG) that is associated with resistance to isoniazid. Similarly, two embB homologues were identified in the M. aurum genome. In addition to describing for the first time the genome of M. aurum, this work provides a resource to aid the use of M. aurum in studies to develop improved drugs for the pathogenic mycobacteria M. tuberculosis and M. leprae.

Citing Articles

C-1 Substituted isoquinolines potentiate the antimycobacterial activity of rifampicin and ethambutol.

Martin L, Lamming E, Maitra A, Mortazavi P, Roddan R, Ward J Front Antibiot. 2025; 2():1095013.

PMID: 39816661 PMC: 11731654. DOI: 10.3389/frabi.2023.1095013.


Reduction of hyperglycemia in STZ-induced diabetic mice by prophylactic treatment with heat-killed : possible effects on glucose utilization, mitochondrial uncoupling, and oxidative stress in liver and skeletal muscle.

Abdallah F, Bazzi S, Akle C, Bahr G, Echtay K Front Endocrinol (Lausanne). 2024; 15:1427058.

PMID: 39377070 PMC: 11456689. DOI: 10.3389/fendo.2024.1427058.


Crystal structure and anti-mycobacterial evaluation of 2-(cyclo-hexyl-meth-yl)-7-nitro-5-(tri-fluoro-meth-yl)benzo[]iso-thia-zol-3(2)-one.

Richter A, Goddard R, Imming P, Seidel R Acta Crystallogr E Crystallogr Commun. 2024; 79(Pt 12):1194-1198.

PMID: 38313133 PMC: 10833412. DOI: 10.1107/S2056989023010137.


Semisynthetic Derivatives of Selected Amaryllidaceae Alkaloids as a New Class of Antimycobacterial Agents.

Maafi N, Al Mamun A, Jandourek O, Marikova J, Breiterova K, Diepoltova A Molecules. 2021; 26(19).

PMID: 34641567 PMC: 8512562. DOI: 10.3390/molecules26196023.


Efflux Pump Inhibition and Resistance Modulation in by and Its Coumarins.

Simunovic K, Solnier J, Alperth F, Kunert O, Mozina S, Bucar F Antibiotics (Basel). 2021; 10(9).

PMID: 34572657 PMC: 8472667. DOI: 10.3390/antibiotics10091075.